Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 0IBRX
0IBRX logo

0IBRX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

No data

No data

News

moomoo
9.0
01-23moomoo
ImmunityBio Stock Falls 2% Following Company’s Mid-Stage Brain Cancer Treatment Data Release
  • Market Reaction: ImmunityBio shares dropped 2% following mid-stage data reports related to their brain cancer treatment.
  • Clinical Development: The data presented is part of ongoing research into the effectiveness of their treatment for brain cancer.
stocktwits
9.0
01-14stocktwits
IBRX Stock Gains Retail Enthusiasm Following Saudi FDA Approval of Company's Bladder Cancer Immunotherapy
  • Expansion Plans: Immunity Bio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa, partnering with local pharmaceutical firm Bio Pharma Cigalah.

  • Clinical Study Update: Enrollment for the QUILT-2005 study evaluating ANKTIVA in early-stage bladder cancer is expected to be completed by Q2 2026, with potential biological license application by the end of the year.

  • Stock Performance: Immunity Bio's stock surged 8% following the approval of ANKTIVA by the Saudi Food and Drug Authority, marking a significant regulatory milestone alongside existing authorizations in the US, UK, and EU.

  • Market Sentiment: Retail sentiment around Immunity Bio remains extremely bullish, with speculation that the approval could double the company's product revenue, reflecting a positive outlook among investors.

Wall Street analysts forecast 0IBRX stock price to rise
0 Analyst Rating
Wall Street analysts forecast 0IBRX stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (0IBRX) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding 0IBRX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (0IBRX) stock price today?

The current price of 0IBRX is 0 USD — it has increased 0

What is (0IBRX)'s business?

What is the price predicton of 0IBRX Stock?

Wall Street analysts forecast 0IBRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 0IBRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (0IBRX)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (0IBRX)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (0IBRX). have?

(0IBRX) has 0 emplpoyees as of March 25 2026.

What is (0IBRX) market cap?

Today 0IBRX has the market capitalization of 0.00 USD.